Weight loss drugs entered a price war. Novo Nordisk launched high-dose Wegovy (7.2mg) at $399 monthly for paying patients - 40% cheaper than Eli Lilly's comparable Zepbound doses.
Standard Wegovy produces roughly 15% weight loss. High-dose achieves 20.7% over 72 weeks. That difference moves from noticeable to transformative.
At $399 monthly, Novo undercuts Eli Lilly by 40%. Over one year of treatment, patients save hundreds of dollars.
High-dose Wegovy launches at 70,000+ US pharmacies on April 8. The FDA approved it on March 19 through priority voucher review.
Insurance coverage decisions matter most. If insurers cover high-dose Wegovy as first-line treatment, Novo could dominate the weight loss market for years.
